Status:
COMPLETED
The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
Nasopharyngeal Carcinoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to verify the role of adding cisplatin chemotherapy to the intensity-modulated radiotherapy (IMRT) for stage II nasopharyngeal carcinoma.
Detailed Description
Clinical Stage II nasopharyngeal carcinoma consisted of T2N0M0, T1N1M0, T2N1M0 three subgroups, the data came from conventional radiotherapy era showed that the prognosis of this three subgroups were ...
Eligibility Criteria
Inclusion
- pathological confirmed squamous cell carcinoma, WHO II-III type,
- clinical stage II (UICC 7th edition, 2009)
- Karnovsky performance score \> 70
- first course of radiotherapy, without radiotherapy and chemotherapy history for other head and neck cancer.
- anticipated life span more than 6 month
- Hemoglobin \> 120g/L, WBC \> 4.0x10\*9/L, Plt \> 100x10\*9/L
- liver and renal function under the 1.25 normal upper limit
- with written consent information
Exclusion
- have other cancer history
- have chemotherapy history
- have radiotherapy history
- have head and neck surgery history(exclusion lymph node biopsy)
- evidence showed distant metastasis or other cancer
- other severe medical comorbidity
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2017
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT01187238
Start Date
May 1 2010
End Date
October 1 2017
Last Update
July 16 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer hospital, Sun Yat-sen University
Guangzhou, Guangdong, China, 510060
2
Zhejiang province cancer hospital
Hangzhou, Zhejiang, China, 310022
3
Cancer hospital, Chinese Academy of Medical Sciences
Beijing, China, 100021